• Daiichi Sankyo and AstraZeneca entered a clinical trial collaboration with Summit Therapeutics in October 2026.
• The collaboration will evaluate Datroway combined with ivonescimab across multiple tumor types, including lung and breast cancers.
• The partners plan to begin with a Phase 3 trial in first-line treatment of triple-negative breast cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610300015BIZWIRE_USPR_____20261029_BW887292) on October 30, 2026, and is solely responsible for the information contained therein.